Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    1.00 (4.65%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Corporate update

19 Jun 2008 07:00

RNS Number : 0476X
Sareum Holdings PLC
19 June 2008
 



19 June 2008

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Corporate Update

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, announced on 2 May 2008, that the Board was undertaking a strategic review to consider how best to take the business forward and create value for shareholders. 

 

On 14 May, the Company announced that as part of the strategic review, the board had implemented a staff restructuring process to reduce its cost base by approximately one third and prepare itself for any potential acquisition or re-financing whilst the future business strategy is under consideration. The restructuring programme has been successfully completed and the Sareum board will continue to review the Company's cost base diligently. In addition, the Company is making progress on a number of fronts and these are described below.

Following announcement of the review on 2 May, Sareum has received expressions of interest in parts or all of its business, particularly its valuable drug discovery programmes, and has received interest in and possible offers to partner, fund, acquire or invest in certain of its programmes or assets. Any transaction resulting from these discussions would lead to an injection of cash into the Company. Initial due diligence is currently being undertaken in respect of several of these discussions. These discussions are at various stages and there is no certainty that any one of them will lead to an offer being made for the Company or any of its assets. The Sareum board continues to actively progress discussions and further announcements will be made as appropriate. 

The Board has concluded, as a result of this review, that the Company should undertake a strategic transaction and it will need to effect a fundraising to enable it to complete such a transaction. In order to facilitate this, the Company will shortly be sending a notice to shareholders convening a general meeting at which shareholders will be asked to give the directors authority to issue further shares for cash. Should the Board decide within a short timescale that strategic transaction is not achievable, the Board will take a decision as to the future of the Company in its present form, as the Company would not be able to continue operations without a significant fundraising.

- Ends-

For further information please contact

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer

 

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 

 

Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett, Colin Aaronson

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQVLFFVQBZBBD
Date   Source Headline
8th Oct 20207:00 amRNSUS Patent Allowance: SDC-1802 TYK2/JAK1 Inhibitor
12th Aug 20207:00 amRNSDetails of Investor Presentation
11th Aug 20207:00 amRNSTrading Statement
29th Jul 20202:05 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
24th Jul 20207:00 amRNSResearch Update
1st Jul 20207:00 amRNSUpdate on Deferred Salaries and Issue of Equity
3rd Jun 202011:06 amRNSSecond Price Monitoring Extn
3rd Jun 202011:00 amRNSPrice Monitoring Extension
3rd Jun 20207:00 amRNSSuccessful Fundraising
2nd Jun 20204:31 pmRNSPrimaryBid.com Offer
2nd Jun 20204:30 pmRNSPlacing to raise £718,500
27th May 20207:00 amRNSSareum to Present at BIO Digital 2020
1st May 20207:00 amRNSBioTrinity Presentation Available Online
28th Apr 20207:00 amRNSCompany Presentation at BioTrinity
20th Apr 202011:00 amRNSPrice Monitoring Extension
17th Apr 202011:05 amRNSSecond Price Monitoring Extn
17th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension
26th Mar 20207:00 amRNSHalf-year Report
26th Mar 20207:00 amRNSGlobal Licensing of FL3+Aurora Programme
12th Mar 20207:00 amRNSPublication: new SRA737 combinations in cancer
17th Dec 20191:36 pmRNSResult of AGM
17th Dec 20197:00 amRNSAGM Statement
20th Nov 20197:00 amRNSNotice of AGM
5th Nov 201910:56 amRNSSareum notes Sierra Oncology Q3 2019 results
30th Oct 20197:00 amRNSResearch Update - SDC-1802 anti-cancer poster
17th Oct 20197:00 amRNSResearch Update - AACR-NCI-EORTC abstract
15th Oct 20197:00 amRNSFinal Results
7th Oct 20197:00 amRNSNotice of Full Year Results
27th Sep 20197:00 amRNSResearch Update - TYK2/JAK1 cancer programme
27th Aug 20197:00 amRNSTrading Statement
16th Aug 20197:00 amRNSChange of Adviser
8th Aug 20192:17 pmRNSSareum notes Sierra Q2 results
29th Jul 20194:29 pmRNSAdditional disclosure concerning Michael Owen
28th Jun 20197:00 amRNSAdditional Funds Raised
27th Jun 20191:50 pmRNSSierra seeks strategic options for SRA737
26th Jun 20197:00 amRNSSuccessful Fundraising
25th Jun 20194:31 pmRNSPrimaryBid.com Offer
25th Jun 20194:30 pmRNSPlacing to progress TYK2/JAK1 programmes
13th Jun 20197:00 amRNSPortfolio Update
3rd Jun 20194:00 pmRNSKey takeaways from SRA737 webcast at ASCO
3rd Jun 201911:05 amRNSSecond Price Monitoring Extn
3rd Jun 201911:00 amRNSPrice Monitoring Extension
3rd Jun 20197:00 amRNSPositive SRA737 data presented at ASCO
16th May 20197:00 amRNSASCO abstracts for SRA737 published
8th May 201912:41 pmRNSSareum notes Sierra Oncology Q1 2019 Results
30th Apr 20197:00 amRNSSareum to Present at BioTrinity 2019 in London
23rd Apr 20197:00 amRNSSRA737 Phase I/IIa data to be presented at ASCO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.